Immunovia
0.658
SEK
+1.39 %
IMMNOV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+1.39%
+10.59%
-28.48%
-24.74%
-25.25%
-26.25%
-97.91%
-99.16%
-95.19%
Immunovia is a biotechnology company. The company's research and development is focused on molecular diagnostics, where the business focuses on driving the development and change of current working methods for diagnosing complex cancers and immune diseases. The vision is to establish blood-based tests to be able to identify different types of pancreatic cancer at an early stage. The company was founded in 2007 and is headquartered in Lund.
Read moreMarket cap
111.67M SEK
Turnover
892.6K SEK
Revenue
1.58M
EBIT %
-18,763.29 %
P/E
-
Dividend yield-%
-
Financial calendar
25/2
2025
Annual report '24
ShowingAll content types
Immunovia AB: Immunovia discovery study published in top protein research journal
Immunovia AB: End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools